Page 195 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023 GEEDL
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
• Real life data: follow-up assessment on Spanish Gaucher disease patients treated
with eliglustat. TRAZELGA project.
Orphanet J Rare Dis. 2023;18(1):390. doi: 10.1186/s13023-023-02939-4.
Serrano-Gonzalo I, de Frutos LL, Lahoz-Gil C, Delgado-Mateos F, Fernández-Galán MÁ, Morales-
Conejo M, Calle-Gordo MV, Ibarretxe-Gerediaga D, Madinaveitia-Ochoa A, Albarracín-Arraigosa
A, Balanzat-Muñoz J, Correcher-Medina P, García-Frade LJ, Hernández-Rivas JM, Labbadia F,
López-Dupla JM, Lozano-Almela ML, Mora-Casterá E, Noya-Pereira MS, Ruíz-Guinaldo MÁ, Del
Mar Tormo-Díaz M, Vitoria-Miñana I, Arévalo-Vargas I, Andrade-Campos M, Giraldo P.
• Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher
Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme
Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher
Disease: Data from the Gaucher Outcome Survey (GOS). J Clin Med. 2022;11:5158”.
J Clin Med. 2023;12(12):4017. doi: 10.3390/jcm12124017.
Hughes DA, Deegan P, Giraldo P, Göker-Alpan Ö, Lau H, Lukina E, Revel-Vilk S, Scarpa M,
Botha J, Gadir N, Zimran A; GOS Steering Committee.
Nacionales
• Déficit de esfingomielinasa ácida lisosomal (ASMD). Revisión de la enfermedad y
tratamiento actual.
en-LISOS-4. 2023.
Villarrubia Espinosa J.
Comunicaciones orales
Congresos internacionales
• Study of miRNA expression profiles depending on the severity of bone involvement
in patients with Gaucher disease.
19th Annual WORLD Symposium. Orlando, US, 21-26 de febrero de 2023.
Serrano I, López de Frutos L, Lahoz C, Roca-Espiau M, Köhler R, Giraldo P.
• New miRNA Bone Biomarkers in Gaucher Disease – a New Concept.
3rd International Conference on Lysosomal Diseases (Med-Lysosomal2023). London, UK,
20-21 April 2023.
Giraldo P.
195